江西三鑫医疗科技股份有限公司 审计报告 大信审字[2023]第 6-00005 号 大信会计师事务所(特殊普通合伙) 审计报告 大信审字[2023]第 6-00005 号 WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查验 6-1-1 WUYIGE Certified Public Accountants U.P. 1 号 15/F.Xuevuan International Tower No.1Zhichun Road,Haidian Dist Beljing,China,100083 江西三鑫医疗科技股份有限公司全体股东: 一、审计意见 我们审计了江西三鑫医疗科技股份有限公司(以下简称"贵公司")的财务报表,包括 2022年12月31日的合并及母公司资产负债表,2022年度的合并及母公司利润表、合并及母 公司现金流量表、合并及母公司股东权益变动表,以及财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反映了 贵公司 2022年 ...

公司本次向不特定对象发行可转换公司债券事项尚需通过深圳证券交易所 审核，并获得中国证券监督管理委员会同意注册的决定后方可实施，该事项能否 通过审核、注册以及最终通过审核、注册的时间仍存在不确定性。公司将根据该 事项的审核进展情况及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告 江西三鑫医疗科技股份有限公司董事会 2025 年 10 月 29 日 关于向不特定对象发行可转换公司债券申请 获得深圳证券交易所受理的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 江西三鑫医疗科技股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日收到深圳证券交易所出具的《关于受理江西三鑫医疗科技股份有限公司向不特 定对象发行可转换公司债券申请文件的通知》（深证上审[2025]209 号），深圳 证券交易所对公司报送的向不特定对象发行可转换公司债券申请文件进行了核 对，认为申请文件齐备，决定予以受理。 证券代码：300453 证券简称：三鑫医疗 公告编号：2025-064 江西三鑫医疗科技股份有限公司 ...

股票简称：三鑫医疗 股票代码：300453 保荐人（主承销商） （成都市青羊区东城根上街 95 号） 二〇二五年十月 江西三鑫医疗科技股份有限公司 Jiangxi Sanxin Medtec Co., Ltd. （江西省南昌县小蓝经济开发区富山大道 999 号） 向不特定对象发行可转换公司债券 募集说明书 （申报稿） 江西三鑫医疗科技股份有限公司 向不特定对象发行可转换公司债券募集说明书 声 明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申请 文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的 盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之相反 的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担证券依法发行后因发行人经营与收益变化或者证券价格变动引致的投资风险。 1-1-1 江西三鑫医疗科技股份有限公司 向不特定对象发行可转换公司债券募集说明书 重大事项提示 公司特别提请投资者注意，在作出投资决策之前，务必仔细阅读本募集说明 书正文内 ...

证券代码：300453 证券简称：三鑫医疗 公告编号：2025-063 江西三鑫医疗科技股份有限公司 关于控股子公司变更医疗器械生产许可证的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 江西三鑫医疗科技股份有限公司（以下简称"公司"）控股子公司成都威力生 生物科技有限公司（以下简称"成都威力生"）因生产经营需要，对《医疗器械生 产许可证》的生产地址进行变更并完成了变更登记手续，于近日取得了四川省药品 监督管理局换发的《医疗器械生产许可证》，现将具体内容公告如下： | 变更事项 | 变更前内容 | 变更后内容 | | --- | --- | --- | | 生产地址 | 高新区科园南路 88 号 10 栋 3 楼 303、304 号；高新区科园南路 88 号 10 栋 3 楼 302 号仓库 5、仓库 6、仓库 7；高新区科韵路 | 高新区科园南路 88 号 10 栋 3 楼 303、304 号；高新区科园南路 88 号 10 栋 3 楼 302 号仓库 5、仓库 6、仓库 7；高新区科韵 路 368 号 1 栋 1 单元 3 楼 301 号；眉山 | | | ...

证券代码：300453 证券简称：三鑫医疗 公告编号：2025-062 江西三鑫医疗科技股份有限公司 关于2024年限制性股票激励计划部分限制性股票 回购注销完成的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、江西三鑫医疗科技股份有限公司（以下简称"公司"）本次回购注销的 股份数量为 313,250 股，占回购前公司总股本 522,397,525 股的 0.06%，本次限 制性股票回购注销涉及的人数为 31 人，回购价格为 3.1 元/股加上银行同期存款 利息之和，回购资金总额为 985,277.05 元（其中限制性股票回购款为 971,075 元，银行同期存款利息为 14,202.05 元）。 2、截至本公告披露之日，上述限制性股票已在中国证券登记结算有限责任 公司深圳分公司完成注销手续。 3、本次回购注销完成后，公司总股本由 522,397,525 股减少为 522,084,275 股。 6、2024 年 9 月 2 日，公司披露了《关于 2024 年限制性股票激励计划授予 登记完成的公告》（公告编号：2024-079），公司完成了本次激 ...

Core Viewpoint - The development of non-toxic medical plastics is crucial due to the health risks associated with DEHP, a common plasticizer in PVC medical devices, which poses reproductive health hazards [1][2][3] Group 1: Health Risks of DEHP - DEHP is widely used in PVC medical devices due to its excellent properties but has significant reproductive toxicity and carcinogenicity [2] - Long-term exposure to DEHP can lead to severe reproductive health issues, including male reproductive system damage and increased miscarriage rates in women [2] - The need for alternatives to DEHP is urgent, as existing substitutes lack reliable safety data and are not developed with domestic intellectual property [2] Group 2: Collaborative Research Efforts - The Beijing Chemical Industry Research Institute is leading a collaborative effort with five other organizations to develop non-phthalate plasticizers [3] - The collaboration encompasses the entire chain from molecular design to production and safety testing, integrating various expertise [3] - Key partners include the Chinese Academy of Sciences and Fudan University, which contribute to the design and safety evaluation of new plasticizers [3] Group 3: Challenges Ahead - The project faces three main challenges: designing a non-toxic molecular structure while avoiding patent barriers, conducting reproductive toxicity assessments, and ensuring compliance with medical standards for production [4] - A production line capable of annual output of 100 tons is planned, with a timeline set for completion of key tasks by June 2028 [4][5] - Successful implementation will lead to the introduction of safer medical devices, such as blood transfusion bags and dialysis tubes, into hospitals [5]

Overview - The demand for hemodialysis in China is rapidly increasing due to a large patient population and the inclusion of end-stage renal disease treatment in major illness insurance, which has improved reimbursement rates, significantly boosting market demand for hemodialysis devices [1][8] - The market size of the hemodialyzer industry in China is projected to reach 5.322 billion yuan in 2024, with a year-on-year growth of 0.48% [1][8] Market Policies - The Chinese government has implemented various policies to support the development of the medical device industry, including hemodialyzers, ensuring market order, product quality, and patient safety [4][5] Industry Chain - The hemodialyzer industry chain consists of upstream suppliers of hollow fibers and dialysis membrane materials, midstream manufacturers producing various types of hemodialyzers, and downstream medical institutions such as public hospitals and independent dialysis centers [6][7] Current Development - The number of hemodialysis patients in China is expected to reach 1.0273 million in 2024, representing a year-on-year increase of 12.04%, with a notable rise in the average age of patients [8] - The male patient proportion is 61.3%, with new male patients accounting for 63.9% [8] Competitive Landscape - The hemodialyzer market in China was initially dominated by foreign companies, but domestic companies like Weigao Blood Purification and Sanxin Medical have been increasing their market share due to improved R&D capabilities and local cost advantages [9][11] - The shift from price competition to quality and innovation is evident, driven by regulatory changes and procurement policies [9] Key Companies - Weigao Blood Purification, a leading player in the blood purification industry, reported a total revenue of 3.604 billion yuan in 2024, with hemodialyzer revenue accounting for 51% of total revenue [11] - Sanxin Medical, established in 1997, achieved a total revenue of 1.5 billion yuan in 2024, with blood purification-related business contributing 81.13% of total revenue [11][12] Future Trends - The implementation of volume-based procurement policies is expected to lower product prices, leading to increased industry concentration as less competitive companies may exit the market [13] - Hemodialyzer companies are likely to offer integrated solutions combining equipment, consumables, and services to enhance customer satisfaction and market competitiveness [13]

Core Viewpoint - The company is implementing a "5G + Smart Factory" digital transformation strategy and advancing AI-enabled engineering construction to enhance operational efficiency and service quality [1] Group 1: Digital Transformation Strategy - The company is deeply engaged in the "5G + Smart Factory" digital transformation strategy [1] - The strategy includes multi-dimensional efforts from production to management [1] - The company aims to develop core AI applications in areas such as intelligent equipment detection and maintenance, as well as smart sales and customer service [1] Group 2: AI Integration - The company is focusing on building an AI knowledge hub platform [1] - The integration of knowledge graphs and automated processes is a key component of the AI strategy [1] - The goal is to effectively consolidate and analyze data to improve business operation efficiency and meet management needs [1] Group 3: Market Influences - The company's stock price is influenced by various factors including macroeconomic conditions, industry policies, and market sentiment [1]

Group 1 - The first integrated CoreVascu artificial blood vessel clinical trial in China has officially launched at the South China Hospital of Shenzhen University, marking a significant milestone for the product [1] - The first patient has been successfully implanted, indicating an efficient start to the clinical trial process [1] - The CoreVascu artificial blood vessel is a collaborative development between Sanxin Medical and Zhejiang University of Science and Technology, breaking the long-standing foreign monopoly in the small-diameter artificial blood vessel market [1]